Breye Therapeutics ApS
APSActiveAdvertising protectionCVR 40279865Agern Alle 24, 2970 HørsholmManufacture of pharmaceutical preparations· NACE 2120Est. 2019 · 7 years old3 employees
Loading company…
Overview
Breye Therapeutics ApS is a Danish APS based in Hørsholm, operating in the Manufacture of pharmaceutical preparations sector. Incorporated in 2019, the company has 3 employees and reported a gross profit of -DKK 7.7m in its latest annual filing.
Gross profit 2026
-7.7M DKK
+1% vs 2025
EBITDA margin (of gross profit)
939.5 %
+13% vs 2025
Net profit 2026
-85.6M DKK
+4% vs 2025
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
-311.0 %
Very weakAmong the 10% lowest rated companies in the industry
20222026
Liquidity ratioCurrent assets ÷ Short-term debt
2.7×
StrongAmong the 30% highest rated companies in the industry
20222026
Return on assets (ROA)Net profit ÷ Total assets × 100
-210.9 %
Very weakAmong the 10% lowest rated companies in the industry
20222026
EBITDA — year on year
DKK millionsKey figures
Annual report 2026| Gross profit | -7.7M DKK | +1% |
| EBITDA | -71.9M DKK | +13% |
| Net profit | -85.6M DKK | +4% |
| Total assets | 40.6M DKK | -29% |
| Equity | -126.2M DKK | -211% |
| Employees | 3 | — |
Company information
Legal name
Breye Therapeutics ApS
CVR number
40279865
Legal form
Anpartsselskab
NACE code
Founded
13 February 2019 · 7 years
Share capital
DKK 341,672
Employees
3 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2026-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af bestyrelsesformanden i forening med et bestyrelsesmedlem eller af bestyrelsesformanden i forening med en direktør eller af den samlede bestyrelse
Company purpose
Selskabets formål er forskning, udvikling og kommercialisering af lægemidler og hermed forbundet virksomhed.
(no translation available)
Contact
Address
Agern Alle 24, 2970 Hørsholm
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2026), Breye Therapeutics ApS reported a gross profit of -DKK 7.7m. The figures on this page draw on 5 annual filings covering 2022 to 2026. The bottom line showed a net loss of DKK 85.6m.
At the end of 2026, current assets covered short-term debt 2.7 times.
Financials
Gross profit
DKK thousandsEBITDA
DKK millionsIncome statement
DKK thousands| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Gross profit | -7,655 | -7,546 | -7,812 | -2,883 | -674 |
| Staff expenses | -8,925 | -7,080 | -6,407 | -1,717 | -64 |
| EBITDA | -71,922 | -82,242 | -74,961 | -19,836 | -738 |
| Depreciation & amort. | -397 | -397 | -411 | -0 | -0 |
| EBIT | -72,319 | -82,639 | -75,372 | -19,836 | -738 |
| Net financials | -18,757 | -12,001 | -273 | -941 | -42 |
| Profit before tax | -91,075 | -94,640 | -75,646 | -20,777 | -780 |
| Tax | -5,500 | -5,500 | -5,496 | -6,202 | -0 |
| Net profit | -85,575 | -89,140 | -70,150 | -14,575 | -780 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Total assets | 40,585 | 57,048 | 60,682 | 24,815 | 18,746 |
| Equity | -126,213 | -40,638 | 48,485 | 14,526 | -752 |
| Long-term debt | 153,788 | 1,944 | 3,767 | 7,101 | 18,478 |
| Short-term debt | 13,011 | 95,741 | 8,430 | 3,188 | 1,020 |
| Total debt | 166,798 | 97,685 | 12,196 | 10,289 | 19,498 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
<−999 %
20222026
Equity ratio
-311.0 %
Very weakAmong the 10% lowest rated companies in the industry
20222026
Return on equity
—
20222026
Net profit margin (of gross profit)
<−999 %
20222026
Asset turnover (of gross profit)
-0.19×
20222026
Debt / equity
—
20222026
Sector performance
17 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on assets (ROA)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Basic earning power (BEP)Very weak
Among the 10% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery weak
Among the 10% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on net assets (RONA)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Liquidity
Current ratioStrong
Among the 30% highest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioStrong
Among the 30% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioVery strong
Among the 20% highest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Fixed assets to long-term capitalAverage
Around the average of companies in the same industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioWeak
Among the 30% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current assets to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Debt & solvency
Solidity ratioVery weak
Among the 10% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery weak
Among the 10% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Income to debtVery weak
Among the 10% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 20% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageWeak
Among the 30% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery weak
Among the 10% lowest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery weak
Among the 10% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Debt to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Efficiency & development
Equity to contributed capitalVery weak
Among the 10% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in debtVery weak
Among the 20% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
One-year change in equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The size of this year's increase or decrease in the company's equity.
Annual reports & filings
- Annual report 2026Filed via CVR / Virk · Period 2025-04-01 – 2026-03-31
- Annual report 2025Filed via CVR / Virk · Period 2024-04-01 – 2025-03-31
- Annual report 2024Filed via CVR / Virk · Period 2023-04-01 – 2024-03-31
- Annual report 2023Filed via CVR / Virk · Period 2022-04-01 – 2023-03-31
- Annual report 2022Filed via CVR / Virk · Period 2021-04-01 – 2022-03-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
UM Chief Executive Officer | Chief Executive Officer | 2019 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (6) | ||
CR Board of Directors | Board of Directors | 2023 |
JS Board of Directors | Board of Directors | 2022 |
GB Board of Directors | Board of Directors | 2022 |
JA Chairman | Chairman | 2022 |
CJ Board of Directors | Board of Directors | 2022 |
UM Board of Directors | Board of Directors | 2022 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 33.33–49.99% | 33.33–49.99% | 2024 | |
Sound Bioventures Fund I AB | Company | 20–24.99% | 20–24.99% | 2023 |
| Company | 10–14.99% | 10–14.99% | 2024 | |
Golgi NueroSciences S.R.L. | Company | 5–9.99% | 5–9.99% | 2024 |
| Company | 5–9.99% | 5–9.99% | 2023 | |
| Company | 10–14.99% | 10–14.99% | 2022 | |
| Individual | 5–9.99% | 5–9.99% | 2020 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Novo Holdings A/S
Breye Therapeutics ApS (this company)Board network connections
Board members of Breye Therapeutics ApS also hold positions in 4 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jørgen Søberg Petersen | Board of Directors | 3 companies |
| Ulrik Mouritzen | Chief Executive Officer | 1 company |
Frequently asked questions
What is the CVR number of Breye Therapeutics ApS?
Breye Therapeutics ApS is registered with CVR / Virk under CVR 40279865.
What is the gross profit of Breye Therapeutics ApS?
Breye Therapeutics ApS reported a gross profit of -DKK 7.7m in 2026.
How many employees does Breye Therapeutics ApS have?
Breye Therapeutics ApS employs 3 people as of the latest annual report.
Who is the CEO of Breye Therapeutics ApS?
Ulrik Mouritzen is the CEO of Breye Therapeutics ApS.
Who is the chairman of Breye Therapeutics ApS?
Jimmy Arnold V Van Heusden chairs the board of Breye Therapeutics ApS, in role since 2022.
Where is Breye Therapeutics ApS headquartered?
Breye Therapeutics ApS's registered address is Agern Alle 24.